Medigen Vaccine Biologics Past Earnings Performance
Past criteria checks 0/6
Medigen Vaccine Biologics's earnings have been declining at an average annual rate of -5.9%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 38.4% per year.
Key information
-5.9%
Earnings growth rate
1.3%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | 38.4% |
Return on equity | -30.2% |
Net Margin | -297.7% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Medigen Vaccine Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 390 | -1,160 | 243 | 1,201 |
30 Sep 23 | 242 | -1,295 | 203 | 851 |
30 Jun 23 | 26 | -1,552 | 172 | 1,058 |
31 Mar 23 | 38 | -1,546 | 178 | 1,009 |
31 Dec 22 | 365 | -1,475 | 184 | 1,140 |
30 Sep 22 | 2,371 | 308 | 171 | 1,259 |
30 Jun 22 | 3,616 | 1,298 | 177 | 1,100 |
31 Mar 22 | 3,604 | 1,427 | 170 | 1,249 |
31 Dec 21 | 3,281 | 1,410 | 148 | 1,193 |
30 Sep 21 | 1,258 | 158 | 134 | 1,090 |
30 Jun 21 | 14 | -706 | 111 | 1,099 |
31 Mar 21 | 14 | -700 | 95 | 833 |
31 Dec 20 | 12 | -674 | 92 | 680 |
30 Sep 20 | 5 | -678 | 78 | 616 |
30 Jun 20 | 2 | -621 | 71 | 539 |
31 Mar 20 | 2 | -611 | 69 | 527 |
31 Dec 19 | 1 | -618 | 66 | 539 |
30 Sep 19 | 1 | -591 | 67 | 512 |
30 Jun 19 | 1 | -557 | 65 | 483 |
31 Mar 19 | 0 | -525 | 68 | 449 |
31 Dec 18 | 0 | -476 | 69 | 397 |
30 Sep 18 | 0 | -424 | 64 | 352 |
30 Jun 18 | 0 | -411 | 61 | 341 |
31 Mar 18 | 0 | -361 | 55 | 300 |
31 Dec 17 | 0 | -340 | 49 | 287 |
30 Sep 17 | 0 | -320 | 52 | 262 |
30 Jun 17 | 0 | -272 | 50 | 229 |
31 Mar 17 | 0 | -235 | 46 | 197 |
31 Dec 16 | 0 | -210 | 42 | 177 |
30 Sep 16 | 0 | -162 | 34 | 139 |
30 Jun 16 | 0 | -173 | 32 | 143 |
31 Mar 16 | 0 | -177 | 29 | 150 |
31 Dec 15 | 0 | -182 | 26 | 157 |
30 Sep 15 | 0 | -166 | 24 | 145 |
30 Jun 15 | 0 | -150 | 22 | 132 |
31 Mar 15 | 0 | -128 | 21 | 110 |
31 Dec 14 | 0 | -105 | 20 | 88 |
Quality Earnings: 6547 is currently unprofitable.
Growing Profit Margin: 6547 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6547 is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare 6547's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6547 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6547 has a negative Return on Equity (-30.15%), as it is currently unprofitable.